357 related articles for article (PubMed ID: 31599424)
1. MicroRNA-1271 inhibits the progression of papillary thyroid carcinoma by targeting IRS1 and inactivating AKT pathway.
Chen Y; Hao SA; Jiang Y; Gao B; Tian WG; Zhang S; Guo LJ; Wang LL; Luo DL
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7989-7999. PubMed ID: 31599424
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-31 inhibits papillary thyroid carcinoma cell biological progression by directly targeting SOX11 and regulating epithelial-to-mesenchymal transition, ERK and Akt signaling pathways.
Wang Y; Liu BG; Zhou CX
Eur Rev Med Pharmacol Sci; 2019 Jul; 23(13):5863-5873. PubMed ID: 31298337
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-26a suppresses the malignant biological behaviors of papillary thyroid carcinoma by targeting ROCK1 and regulating PI3K/AKT signaling pathway.
Wu YC; Li SY; Jia YF
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(20):8940-8949. PubMed ID: 31696481
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-486 inhibits cell proliferation, invasion and migration via down-regulating the TENM1 expressions and affecting ERK and Akt signaling pathways and epithelial-to-mesenchymal transition in papillary thyroid carcinoma.
Sun YH; Liu ZF; Yang BB; Yu B
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8429-8439. PubMed ID: 31646573
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-203 restrains epithelial-mesenchymal transition, invasion and migration of papillary thyroid cancer by downregulating AKT3.
You A; Fu L; Li Y; Li X; You B
Cell Cycle; 2020 May; 19(10):1105-1121. PubMed ID: 32308106
[TBL] [Abstract][Full Text] [Related]
6. miR-215 suppresses papillary thyroid cancer proliferation, migration, and invasion through the AKT/GSK-3β/Snail signaling by targeting ARFGEF1.
Han J; Zhang M; Nie C; Jia J; Wang F; Yu J; Bi W; Liu B; Sheng R; He G; Kong L; Zheng L; Pang R; Ding Z; Chen L; Guan Q; Pan S; Meng X; Xu J; Liu L; Zhang J
Cell Death Dis; 2019 Feb; 10(3):195. PubMed ID: 30814512
[TBL] [Abstract][Full Text] [Related]
7. miRNA-21 promotes cell proliferation and invasion via VHL/PI3K/AKT in papillary thyroid carcinoma.
Zang C; Sun J; Liu W; Chu C; Jiang L; Ge R
Hum Cell; 2019 Oct; 32(4):428-436. PubMed ID: 31161410
[TBL] [Abstract][Full Text] [Related]
8. microRNA-539 functions as a tumor suppressor in papillary thyroid carcinoma via the transforming growth factor β1/Smads signaling pathway by targeting secretory leukocyte protease inhibitor.
Xu CB; Liu XS; Li JQ; Zhao X; Xin D; Yu D
J Cell Biochem; 2019 Jun; 120(6):10830-10846. PubMed ID: 30706537
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA‑766 inhibits papillary thyroid cancer progression by directly targeting insulin receptor substrate 2 and regulating the PI3K/Akt pathway.
Zhao J; Li Z; Chen Y; Zhang S; Guo L; Gao B; Jiang Y; Tian W; Hao S; Zhang X
Int J Oncol; 2019 Jan; 54(1):315-325. PubMed ID: 30387841
[TBL] [Abstract][Full Text] [Related]
10. MiR-192-5p inhibits proliferation, migration, and invasion in papillary thyroid carcinoma cells by regulation of SH3RF3.
Fu S; Ma C; Tang X; Ma X; Jing G; Zhao N; Ran J
Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34486645
[TBL] [Abstract][Full Text] [Related]
11. Exosomal circular RNA hsa_circ_007293 promotes proliferation, migration, invasion, and epithelial-mesenchymal transition of papillary thyroid carcinoma cells through regulation of the microRNA-653-5p/paired box 6 axis.
Lin Q; Qi Q; Hou S; Chen Z; Jiang N; Zhang L; Lin C
Bioengineered; 2021 Dec; 12(2):10136-10149. PubMed ID: 34866540
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-222 Promotes Invasion and Metastasis of Papillary Thyroid Cancer Through Targeting Protein Phosphatase 2 Regulatory Subunit B Alpha Expression.
Huang Y; Yu S; Cao S; Yin Y; Hong S; Guan H; Li Y; Xiao H
Thyroid; 2018 Sep; 28(9):1162-1173. PubMed ID: 29882471
[TBL] [Abstract][Full Text] [Related]
13. microRNA-599 promotes apoptosis and represses proliferation and epithelial-mesenchymal transition of papillary thyroid carcinoma cells via downregulation of Hey2-depentent Notch signaling pathway.
Wang DP; Tang XZ; Liang QK; Zeng XJ; Yang JB; Xu J
J Cell Physiol; 2020 Mar; 235(3):2492-2505. PubMed ID: 31565805
[TBL] [Abstract][Full Text] [Related]
14. MiR-630 inhibits papillary thyroid carcinoma cell growth, metastasis, and epithelial-mesenchymal transition by suppressing JAK2/STAT3 signaling pathway.
Pan XM; He XY; Yang YL; Jia WJ; Yang ZQ; Yan D; Ma JX
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(6):2453-2460. PubMed ID: 30964171
[TBL] [Abstract][Full Text] [Related]
15. Circ_0079558 promotes papillary thyroid cancer progression by binding to miR-26b-5p to activate MET/AKT signaling.
Zheng H; Fu Q; Ma K; Shi S; Fu Y
Endocr J; 2021 Nov; 68(11):1247-1266. PubMed ID: 34565758
[TBL] [Abstract][Full Text] [Related]
16. MiR-577 inhibits papillary thyroid carcinoma cell proliferation, migration and invasion by targeting SphK2.
Xue KC; Hu DD; Zhao L; Li N; Shen HY
Eur Rev Med Pharmacol Sci; 2017 Oct; 21(17):3794-3800. PubMed ID: 28975989
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-520a-3p suppresses epithelial-mesenchymal transition, invasion, and migration of papillary thyroid carcinoma cells via the JAK1-mediated JAK/STAT signaling pathway.
Bi CL; Zhang YQ; Li B; Guo M; Fu YL
J Cell Physiol; 2019 Apr; 234(4):4054-4067. PubMed ID: 30206929
[TBL] [Abstract][Full Text] [Related]
18. MiR-96-5p promotes the proliferation, invasion and metastasis of papillary thyroid carcinoma through down-regulating CCDC67.
Liu ZM; Wu ZY; Li WH; Wang LQ; Wan JN; Zhong Y
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3421-3430. PubMed ID: 31081096
[TBL] [Abstract][Full Text] [Related]
19. Long non-coding RNA TTN-AS1 facilitates tumorigenesis of papillary thyroid cancer through modulating the miR-153-3p/ZNRF2 axis.
Cui Z; Luo Z; Lin Z; Shi L; Hong Y; Yan C
J Gene Med; 2019 May; 21(5):e3083. PubMed ID: 30811764
[TBL] [Abstract][Full Text] [Related]
20. Long noncoding RNA PVT1 enhances the viability and invasion of papillary thyroid carcinoma cells by functioning as ceRNA of microRNA-30a through mediating expression of insulin like growth factor 1 receptor.
Feng K; Liu Y; Xu LJ; Zhao LF; Jia CW; Xu MY
Biomed Pharmacother; 2018 Aug; 104():686-698. PubMed ID: 29803929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
